AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06375772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Deoxy-D-glucose
Description: Intranasal administration
Study NCT06375772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal administration
Study NCT05574244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial surgery preserving the prostatic apex
Description: Partial Endoscopic resection of prostate to conserve apex
Study NCT05574244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional endoscopic prostatic surgery
Description: Endoscopic resection of prostate.
Study NCT05250557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve
Description: Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
Study NCT06645704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP262
Description: Single dose of \[14C\]-EP262 administered orally.
Study NCT03660722 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood and urinary samples
Description: blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
Study NCT05471856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1703880
Description: BI 1703880
Study NCT05471856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab
Study NCT05159960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
Study NCT06782425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XKDCT225
Description: Autologous targeted claudin18.2 chimeric antigen receptor T cell injection
Study NCT06781606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile transplantation
Description: The penile transplantation will take place at the Edouard Herriot hospital, part of the Hospices Civils de Lyon. It will be carried out on the same day or the day after the harvesting depending on the timing of the harvesting.
Study NCT06780059 — intervention group
Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: Postoperative Radiotherapy with 3D-CRT and IMRT Techniques Following R0 Resection in BoPT and MPT Patients
Study NCT04135443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3T Tune in! Turn on! Turn up!
Description: A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-19. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
Study NCT04135443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Materials Website
Description: The control group will receive access to a website containing general health promotion materials.
Study NCT06324110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06324110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06780059 — intervention group
Intervention type: PROCEDURE
Intervention: R0 resection
Description: Patients who received R0 resection (complete resection without tumor margin)
Study NCT06781528 — intervention group
Intervention type: OTHER
Intervention: Ultrasound evaluation
Description: All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.
Study NCT06780202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medrol dosepak
Description: Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression.~This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg).
Study NCT06324110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Receive lung cancer screening care coordination services
Study NCT06345703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-136 matching placebo
Study NCT06780202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYDROcodone Oral Tablet
Description: This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
Study NCT06345703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136
Study NCT06780202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HYDROcodone Oral Tablet
Description: This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
Study NCT06781294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Cytokine hemadsorption therapy
Description: Extracorporeal blood purification with oXiris set connected to cardiopulmonary bypass during all CPB time. Ultrafiltration was permitted.
Study NCT06782217 — intervention group
Intervention type: BIOLOGICAL
Intervention: VENOX
Description: Treatment with allergy vaccine againts Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
Study NCT05001165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Panel Management Clinics for HFrEF
Description: Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
Study NCT05217966 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: Single Pre-Operative Radiation Therapy
Description: Ablative preoperative partial breast radiation therapy
Study NCT05996445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb662
Description: Intravenous (IV) administration
Study NCT05996445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keytruda® (pembrolizumab)
Description: Intravenous (IV) administration
Study NCT05627986 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05647122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9592
Description: Varying doses of AZD9592
Study NCT05647122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: tablets administered orally
Study NCT05647122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: IV infusion
Study NCT05647122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV infusion
Study NCT05647122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study NCT06406478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schedule Change
Description: This 4-day workweek is defined by any 4 ten hour shifts between Sunday and Saturday. It will be up to the discretion of participants in the intervention group to coordinate which 4 days they work. The 4 days will most likely be weekdays, but some participants may work weekends. If participants do any work from home, they will clock in remotely to account for the time.
Study NCT06406478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Schedule Change
Description: The control group will continue to work five days per week, receiving standard practice for the schedule policies at the participating study sites.
Study NCT06780813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental oxygen therapy
Description: In this grou participants will receive supplemental oxygen in the form of a Venturi mask upon low oxygen saturation in oximetry (SaO2\<95%) and a nasal oxygen mask in all other cases during the first 2 postoperative days
Study NCT04605263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-PPN DBS Surgery
Description: Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
Study NCT04605263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation Surgery (DBS)
Description: DBS lead implantation of bilateral STN
Study NCT05121493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Poor Plasma Tear Drops
Description: Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.
Study NCT05121493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Tear Drops
Description: Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
Study NCT04934943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mini_FC
Description: 100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording
Study NCT05929755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol
Description: steroid
Study NCT05929755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel-Flow NT
Description: hemostatic agent
Study NCT05929755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gel-Flow NT
Description: hemostatic agent
Study NCT05497700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg
Study NCT05497700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
Study NCT05672082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714
Description: Participant received one injection of 200 MBq of \[18F\]DPA-714
Study NCT05978648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: 240 mg/m2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
Study NCT05978648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
Study NCT05978648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
Study NCT05978648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, intravenous drip, d1,8,15, Q3W, 4 cycles.
Study NCT05978648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, intravenous drip, d1, Q3W, 6 cycles.
Study NCT05978648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: area under curve(AUC) = 6, intravenous drip, d1, Q3W, 6 cycles.
Study NCT05978648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg in Cycle 1, 6 mg/kg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
Study NCT05978648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840mg in Cycle 1, 420mg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
Study NCT06018597 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL
Description: No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
Study NCT04847479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 self-test
Description: Up to 3 COVID-19 self-test kits will be given to individuals who have tested positive for COVID-19. Participants will be instructed to give test kits to close contacts who have been exposed to them.
Study NCT04847479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 test referral
Description: Text messages with testing information will be given to individuals who have tested positive for COVID-19. Participants will be instructed to share text messages with close contacts who have been exposed to them.
Study NCT06397547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped Learning
Description: Materials for students' pre-class studies and for use by the instructor during class will be created by the researchers. For students in the experimental group to come prepared for class according to the flipped learning model, digital materials will be prepared by the researchers. The experimental group will receive digital materials prior to the topic. The links to these materials will be sent to the students, who can access them via their mobile phones and watch the explanatory and demonstration videos as many times as they wish. Subsequently, the topic will be presented to the students. They will summarize the information learned from the videos and engage in question-answer sessions and discussions using prepared digital resources to address any points they do not understand. To reinforce the practices in the experimental group, online word clouds and quizzes will be sent.
Study NCT05171647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
Study NCT05171647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
Study NCT05171647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
Study NCT05171647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Study NCT05171647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Study NCT05171647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Study NCT05044611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anhydrous Amiloride Hydrochloride
Description: Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase
Study NCT05044611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Route of administration : oral the control arm will receive a placebo twice daily during 2 months
Study NCT06402604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: See above in arm group descriptions.
Study NCT06402604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction training
Description: See above in arm group descriptions.
Study NCT04871308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.
Study NCT04871308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
Study NCT04862663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion
Study NCT04862663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
Study NCT05366582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes
Study NCT04816773 — intervention group
Intervention type: DEVICE
Intervention: EVOLUTION® NitrX™
Description: EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
Study NCT04862663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
Study NCT04862663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.
Study NCT04862663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.
Study NCT04862663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle
Study NCT05144516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: COPE +
Description: Six sixty minute sessions that teaches participants distress and communication coping skills.
Study NCT05599880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
Study NCT05422222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination for oral administration.
Study NCT05313256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine epinephrine buffered with sodium bicarbonate
Description: When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
Study NCT05313256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine epinephrine
Description: When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
Study NCT04860336 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT05807893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab combined with bevacizumab and first-line chemotherapy
Description: Serplulimab combined with bevacizumab and first-line chemotherapy